Organisation paid for research Program year 2025 Source: CMS Open Payments

Valley View Research

Neither a doctor nor a teaching hospital

Research payments

$77,684

15 payments

Through program year 2025, Valley View Research is reported as receiving $77,684 in research payments, across 15 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$44,214	9
2024	Research	$33,470	6

Breakdown

Who paid Research payments · program years 2024–2025

Genentech, Inc. $42,140 8 payments
Takeda Pharmaceuticals U.S.A., Inc. $22,144 6 payments
Eli Lilly and Company $13,400 1 payment

Studies the money was for Research payments · program years 2024–2025

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) $21,070 4 payments
VEDOLIZUMABSC-3003 An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohns Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy $17,400 3 payments
UC P3: Double-Blind Induction $16,070 3 payments
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone Or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis $13,400 1 payment
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) $5,000 1 payment
An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohns Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy $4,744 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.